Luxna Biotech is a preclinical antisense drug development company based on proprietary modified nucleic acids, unique bridged structure (AmNA, scpBNA, GuNA) and modified DNA (5'-CP) can eliminate phosphorothioated in antisense and siRNA. Currently, better modifications are being discovered that are suitable for applications in neurological diseases that minimize neurotoxicity while maintaining knockdown efficacy in vivo by Gapmer. Based on these findings we developed excellent antisense (ASO) drug discovery platform called “LuxiAPTM” enable to wide therapeutic index for CNS ASO drug. We have several pharmaceutical collaborations and original ASO pipeline including ALS, Spinal cord injury and Hearing loss. We are looking for the partners not only for platform collaboration with pharmaceuticals and biotech but early-stage co-development alliance with our original pipeline.
Company Details
- Employees
- 9
- Founded
- 2017
- Address
- 2-8 Yamadaoka, Suita,osaka 565-0871,japan
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://luxnabiotech.co.jp/en/
- HQ
- Suita, Osaka
Luxna Biotech Co., Ltd. Questions
Luxna Biotech Co., Ltd.'s website is https://luxnabiotech.co.jp/en/
Luxna Biotech Co., Ltd.'s LinkedIn profile is https://jp.linkedin.com/company/luxnabiotech
Luxna Biotech Co., Ltd. has
9 employees.
View email and phone details for 9
employees at Luxna Biotech Co., Ltd..
Luxna Biotech Co., Ltd.'s industry is
Biotechnology Research
Luxna Biotech Co., Ltd.'s top competitors are
Kiko Tech Co.,ltd,
Pangaea, Inc. パンゲア株式会社,
Clea Japan, Inc.,
Minaris Advanced Therapies,
Revascular Bio,
Alnylam Pharmaceuticals,
Nomura Siam International Co., Ltd.,
株式会社フィジオスバイオテック、physios Biotech, Inc.,
Fet Open Gladiator,
Cellusion Inc..
Luxna Biotech Co., Ltd.'s categories are Biotechnology Research
Luxna Biotech Co., Ltd.'s founding year is 2017
